Fewer patients will be receiving the erythropoiesis-stimulating agents Eprex (epoetin) and Aranesp (darbepoetin)
June 2007
Fewer patients will be receiving the erythropoiesis-stimulating agents Eprex (epoetin) and Aranesp (darbepoetin).
Chronic kidney disease. Erythropoiesis-stimulating agents (ESAs) are associated with an increase in death and cardiovascular events when used to boost hemoglobin above 120 g/L.
These drugs can increase thrombosis risk.
Practical advice for a better career, with unlimited access to CE
Pharmacy Technician's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 120+ CE courses, including the popular CE-in-the-Letter
- Helpful, in-depth Technician Tutorials
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote